GPCR Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of -- compared to Structure Therapeutics, Inc.'s net margin of 31.72%. Structure Therapeutics, Inc.'s return on equity of -25.55% beat Eli Lilly & Co.'s return on equity of 106.26%.

Structure Therapeutics, Inc. has a consensus price target of $99.43, signalling upside risk potential of 39.47%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 2.01%. Given that Structure Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Structure Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Structure Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Structure Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Structure Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Structure Therapeutics, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Structure Therapeutics, Inc.'s net income of -$65.8M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Structure Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 53.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics, Inc. is -- versus 16.44x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk A/S has a net margin of -- compared to Structure Therapeutics, Inc.'s net margin of 26.68%. Structure Therapeutics, Inc.'s return on equity of -25.55% beat Novo Nordisk A/S's return on equity of 68.76%.

Structure Therapeutics, Inc. has a consensus price target of $99.43, signalling upside risk potential of 39.47%. On the other hand Novo Nordisk A/S has an analysts' consensus of $53.33 which suggests that it could grow by 3.33%. Given that Structure Therapeutics, Inc. has higher upside potential than Novo Nordisk A/S, analysts believe Structure Therapeutics, Inc. is more attractive than Novo Nordisk A/S.

Structure Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novo Nordisk A/S has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.994%.

Structure Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk A/S offers a yield of 3.35% to investors and pays a quarterly dividend of $0.58 per share. Structure Therapeutics, Inc. pays -- of its earnings as a dividend. Novo Nordisk A/S pays out 35.93% of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Structure Therapeutics, Inc. quarterly revenues are --, which are smaller than Novo Nordisk A/S quarterly revenues of $11.7B. Structure Therapeutics, Inc.'s net income of -$65.8M is lower than Novo Nordisk A/S's net income of $3.1B. Notably, Structure Therapeutics, Inc.'s price-to-earnings ratio is -- while Novo Nordisk A/S's PE ratio is 15.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics, Inc. is -- versus 4.92x for Novo Nordisk A/S. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -- compared to Structure Therapeutics, Inc.'s net margin of 21.32%. Structure Therapeutics, Inc.'s return on equity of -25.55% beat Pfizer Inc.'s return on equity of 10.84%.

Structure Therapeutics, Inc. has a consensus price target of $99.43, signalling upside risk potential of 39.47%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 15.04%. Given that Structure Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Structure Therapeutics, Inc. is more attractive than Pfizer Inc..

Structure Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Structure Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Structure Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Structure Therapeutics, Inc. quarterly revenues are --, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Structure Therapeutics, Inc.'s net income of -$65.8M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Structure Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics, Inc. is -- versus 2.26x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of -- compared to Structure Therapeutics, Inc.'s net margin of --. Structure Therapeutics, Inc.'s return on equity of -25.55% beat Viking Therapeutics, Inc.'s return on equity of -28.62%.

Structure Therapeutics, Inc. has a consensus price target of $99.43, signalling upside risk potential of 39.47%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $93.39 which suggests that it could grow by 156.49%. Given that Viking Therapeutics, Inc. has higher upside potential than Structure Therapeutics, Inc., analysts believe Viking Therapeutics, Inc. is more attractive than Structure Therapeutics, Inc..

Structure Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.649, suggesting its less volatile than the S&P 500 by 35.072%.

Structure Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Structure Therapeutics, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

Structure Therapeutics, Inc. quarterly revenues are --, which are smaller than Viking Therapeutics, Inc. quarterly revenues of --. Structure Therapeutics, Inc.'s net income of -$65.8M is higher than Viking Therapeutics, Inc.'s net income of -$90.8M. Notably, Structure Therapeutics, Inc.'s price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Structure Therapeutics, Inc. is -- versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.